Lance-Adams综合征的治疗、诊断方法与长期结局
本研究为三所三级转诊医院的回顾性综述,纳入2010年1月1日至2022年6月30日诊断的39例Lance-Adams综合征患者,描述其治疗、诊断方法及长期临床结局。最常见初始治疗为左乙拉西坦(26例,67%),其次为丙戊酸(4例,10.3%);多数患者需第二种药物(28例,72%),最常见二线药物为苯二氮䓬类(13例,48%)。33例(85%)肌阵挛随时间改善,30例(77%)达到症状控制,住院诊断者达到症状控制的中位时间为70天。6个月随访时8例(23%)CPC评分为1,11例(30%)为2;13例尝试减药,其中6例(46%)成功。结论认为多数患者经左乙拉西坦、丙戊酸或苯二氮䓬类治疗后肌阵挛改善,但常需多种药物和长期治疗,半数患者6个月时功能结局良好。
要点
- 39例Lance-Adams综合征患者中,最常见初始治疗为左乙拉西坦(26例,67%),其次为丙戊酸(4例,10.3%)。
- 初始左乙拉西坦治疗者22例(85%)症状改善,初始丙戊酸治疗者4例(100%)症状改善。
- 28例(72%)需第二种药物,最常见二线药物为苯二氮䓬类(13例,48%)。
- 33例(85%)肌阵挛随时间改善,30例(77%)达到症状控制;住院诊断者达到症状控制的中位时间为70天。
- 6个月随访时8例(23%)CPC评分为1、11例(30%)为2;13例尝试减药,6例(46%)成功。
适用人群与场景
- 三所三级转诊医院中2010年1月1日至2022年6月30日诊断为Lance-Adams综合征的患者,共39例。
- 25例在心脏骤停后急性住院期间诊断,其余在门诊诊断。
诊断标准与关键阈值
- Lance-Adams综合征诊断:心肺复苏后觉醒数天至数月内出现动作性肌阵挛。
- 症状控制定义:残留肌阵挛轻微或无,不造成日常生活活动功能损害。
- 功能结局采用6个月时脑功能分级(CPC)评估。
处置流程与药物剂量
- 最常见初始治疗为左乙拉西坦(26例,67%),其次为丙戊酸(4例,10.3%);原文未报告具体剂量、给药途径和频次。
- 28例(72%)需第二种药物,最常见二线药物为苯二氮䓬类(13例,48%);原文未报告具体药名、剂量和用法。
- 13例(33%)尝试减药,其中6例(46%)成功;原文未报告减药方案和疗程。
研究设计与关键结果
- 回顾性综述,三所三级转诊医院,39例Lance-Adams综合征患者,描述治疗、诊断方法及长期临床结局。
- 初始左乙拉西坦治疗者22例(85%)症状改善,初始丙戊酸治疗者4例(100%)症状改善。
- 33例(85%)肌阵挛随时间改善,30例(77%)达到症状控制;住院诊断者达到症状控制的中位时间为70天。
- 6个月随访时8例(23%)CPC评分为1,11例(30%)CPC评分为2。
- 13例(33%)尝试减药,其中6例(46%)成功。
证据类型、等级与局限
- 证据类型:回顾性综述(三所三级转诊医院)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为多数Lance-Adams综合征患者经左乙拉西坦、丙戊酸或苯二氮䓬类治疗后肌阵挛改善,但常需多种药物和长期治疗。
- 作者认为半数患者6个月时达到良好功能结局(CPC评分1或2)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Lance-Adams syndrome (LAS) is a rare neurological complication following cardiopulmonary resuscitation. Patients present with action myoclonus within days to months after awakening. There is no established first-line treatment. The objectives of this study were to describe treatments, diagnostic approaches, and long-term clinical outcomes for LAS.
METHODS: We performed a retrospective review of patients seen at three tertiary referral hospitals. An electronic database was used to identify all patients diagnosed with LAS from January 1, 2010, to June 30, 2022. Demographics, diagnostics, treatments, and long-term clinical outcomes were extracted. Descriptive statistics were completed to summarize treatments, diagnostics, and clinical outcomes, which were assessed by Cerebral Performance Category (CPC) at 6 months. Symptom control was defined as minimal or no residual myoclonus causing functional impairment on activities of daily living.
RESULTS: Thirty-nine patients met inclusion criteria. A total of 25 patients were diagnosed with LAS during the acute hospitalization after their cardiac arrest, and the rest were diagnosed in the outpatient setting. The most common initial treatment was levetiracetam (n = 26; 67%) followed by valproic acid (n = 4; 10.3%). Most patients initially treated with levetiracetam (n = 22; 85%) or valproic acid (n = 4; 100%) had symptom improvement. Most patients (n = 28; 72%) required a second medication. The most common second-line agent was a benzodiazepine (n = 13; 48%). Thirty-three patients (85%) had improvement of the myoclonus over time. Thirty (77%) were able to achieve symptom control. The median time to achieve symptom control for patients diagnosed in the inpatient setting was 70 days. At the 6-month follow-up, 8 patients (23%) achieved a CPC score of 1, whereas 11 patients (30%) had a CPC score of 2. Thirteen patients (33%) attempted to wean off their medications, of which six patients (46%) were successful.
CONCLUSIONS: Most patients with LAS experienced improvement of their myoclonus while being treated with levetiracetam, valproic acid, or benzodiazepines, although multiple medications and long-term treatment were often used. Half the patients attained favorable functional outcomes at 6 months.
参考来源
- Xeros H, Sakusic A, Fugate JE, et al. Treatment, Diagnostic Approach, and Long-Term Outcomes of Lance-Adams Syndrome. Neurocrit Care. 2025. PMID: 40551063. doi:10.1007/s12028-025-02307-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。